Abstract
To evaluate the efficacy and safety of the combination of cellex with basic therapy in patients with ischemic stroke in the acute stage. An analytical prospective, randomized, simple, blind study included 52 patients with ischemic stroke. The main group of patients (n=26) was treated with basic therapy, which included hypotensive drugs, antiaggregants or anticoagulants depending on the concomitant pathology as well as vascular medications. In addition the patients received cellex in dose 0.1 mg daily during 10 days. The control group (n=26) received basic therapy. Along with assessment of neurological status, the Glasgow coma scale, the National Institute of Health stroke scale (NIHSS), the Barthel Index, the modified Rankin Scale, the MMSE, the Speech Function Score Scale, Speech Questionnaire were used on admission to the hospital, on the 5th, 10th day and on the day of discharge. A positive influence of cellex on the restoration of neurologic functions, mainly motor functions, was observed. Cellex has a good tolerability profile. The use of cellex together with basic therapy of ischemic stroke allows shortening the period of hospitalization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
